Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.
Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.
Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...
A multilevel, navigation-based intervention led to more timely initiation of postoperative radiation therapy vs. usual ...
Non-communicable diseases rank among the most serious global health challenges of the 21st century due to their high prevalence and substantial socioeconomic and health-care impact. According to WHO, ...
The risk of developing liver cancer is increased in people who have cirrhosis, a disease in which healthy liver tissue is ...
Researchers describe successful tumor removal through the use of immunotherapy and targeted radiation therapy (TARE), in a patient previously considered ineligible for the procedure.
The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...
TheraBionic is the only FDA-approved therapy indicated in liver cancer patients that fail first-line and second-line therapy, so that's really the place it takes right now in 2025. Patients can ...
In this video, Annick Desjardins, MD, professor of neurosurgery, professor of neurology and member of the Duke Cancer Institute, explains how clinicians may treat patients with gliomas of different ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback